The Continuous Pulse Oximeter (CPO-2) is a conceptual wearable device designed for infants with Bronchopulmonary Dysplasia (BPD) and other patient populations requiring continuous oxygen monitoring. The National Institutes of Health estimates that 10,000-15,000 babies born in the United States develop BPD each year. Inspired by the concept of continuous glucose monitors (CGMs), the CPO-2 aims to offer a wireless, adhesive solution to address the challenges associated with traditional pulse oximeters.

The intellectual property involves creating a device that is capable of reading oxygen saturations (spO2) without the need for a separate machine. Unlike current pulse oximeters that are minimally adhesive and connected to a machine via a cord, the CPO-2 would transmit information directly to a smartphone, eliminating the machine and cord, thereby reducing the risk of strangulation and skin breakdown issues. The adhesive component is expected to last for an extended period, potentially 7-10 days or more, reducing the need for frequent probe replacements.

Potential applications include adoption by home care companies, which could provide the CPO-2 to families taking infants or children home on oxygen. The device could find utility across various age groups, offering a less cumbersome method for continuous oxygen saturation monitoring.

RINCH has filed a provisional application (63/533,946) and the inventor continues to develop and refine this technology.